Resistance to New Antiretroviral Agents Session Posters

A molecular model of HIV-1 integrase inhibitor resistance
D Hazuda

Novel small-molecule compounds which inhibit strand transfer activity of HIV-1 integrase
W Sugiura

In vitro development of resistance against styrylquinolines of HIV-1 by emergence of integrase mutations
A Chéret

Selection for and characterization of HIV-1 isolates resistant to the maturation inhibitor PA-457
C Wild

In vitro resistance profile of small molecule HIV attachment inhibitors
PF Lin

In vitro escape of R5 primary isolates from the CCR5 antagonist, UK-427,857, is difficult and involves continued use of the CCR5 receptor
M Westby

Suppression of X4- and dual-tropic HIV-1 variants during a short course of monotherapy with the CXCR4 antagonist AMD3100
W Huang

Withdrawal of fusion inhibitors from a failing antiretroviral regimen results in reversion to enfuvirtide susceptibility
GD Miralles

A human monoclonal antibody blocks HIV entry by a T20-like mechanism
MD Miller

Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100
G Sévigny

Phenotypic and genotypic resistance to a new protease inhibitor, 640385, in HIV-1 virus samples from subjects failing amprenavir
A Florance

In vitro selection and characterization of resistance to the new HIV protease inhibitor GW640385
P Yates

Antiviral activity and resistance profile of AG-001859, a novel HIV-1 protease inhibitor with potent activity against protease inhibitor-resistant strains of HIV
J Hammond

Highly potent HIV protease inhibitors with broad activity against MDR strains
SV Gulnik

Analysis of time of failure genotype and phenotype from NNRTI-experienced patients treated with capravirine
J Hammond

In vitro resistance development for a second-generation NNRTI: TMC125
G Heilek-Snyder

Dioxolane-thymine nucleoside (DOT) against drug-resistant HIV-1 mutants and its molecular mechanism
CK Chu

Impact of residue 50 substitutions on phenotypic susceptibility to protease inhibitors
DW Seekins